Specialized Self-Emulsifying Cannabidiol Formulations for Niche Applications

Publication ID: 24-11857678_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Self-Emulsifying Cannabidiol Formulations for Niche Applications,” Published Technical Disclosure No. 24-11857678_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857678_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,678.

Summary of the Inventive Concept

This inventive concept adapts self-emulsifying cannabidiol formulations for specific, narrow markets or unique operational environments, such as treating opioid addiction, chronic pain in chemotherapy patients, veterinary use, anxiety disorders in children, and sleep disorders in the elderly.

Background and Problem Solved

The original patent disclosed self-emulsifying cannabidiol compositions for general therapeutic applications. However, certain niche markets or operational environments require specialized formulations that address specific challenges, such as extreme temperatures, pediatric or veterinary use, or specific disease indications. The present inventive concept addresses these limitations by providing tailored formulations for these unique applications.

Detailed Description of the Inventive Concept

The new inventive concept comprises self-emulsifying cannabidiol formulations adapted for specific niche applications. Claim 1 addresses opioid addiction by incorporating an opioid receptor antagonist. Claim 2 targets chronic pain in chemotherapy patients by formulating the composition to withstand extreme temperatures. Claim 3 is designed for veterinary use, incorporating a flavoring agent. Claim 4 addresses anxiety disorders in children, utilizing a pediatric-friendly excipient. Claim 5 focuses on treating sleep disorders in the elderly, incorporating a sleep-promoting agent. These specialized formulations ensure optimal performance and efficacy in their respective applications.

Novelty and Inventive Step

The novelty of this inventive concept lies in the adaptation of self-emulsifying cannabidiol formulations for specific, narrow markets or unique operational environments. The inventive step resides in the selection of specific components, such as opioid receptor antagonists, flavoring agents, pediatric-friendly excipients, or sleep-promoting agents, which enable the formulations to address the particular challenges of each niche application.

Alternative Embodiments and Variations

Alternative embodiments of this inventive concept could include formulations adapted for disaster relief, high-security needs, or extreme weather conditions. Variations could involve different surfactants, oils, or antioxidants to optimize performance in specific applications.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential in various industries, including pharmaceuticals, veterinary medicine, and nutraceuticals. The specialized formulations can be marketed to address specific therapeutic needs, such as opioid addiction, chronic pain, anxiety disorders, or sleep disorders, in various patient populations.

CPC Classifications

SectionClassGroup
A A61 A61K9/107
A A61 A61K9/4808
A A61 A61K9/4825
A A61 A61K31/05
A A61 A61K47/10
A A61 A61K47/14
A A61 A61K47/22

Field of Art

Pharmaceutical formulations, specifically cannabidiol delivery systems, with expertise in self-emulsifying drug delivery technologies, surfactant interactions, and specialized medical compositions

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with advanced degree in pharmaceutical sciences or chemical engineering, experienced in drug delivery systems, familiar with cannabinoid formulation techniques, surfactant interactions, and excipient selection

Obviousness Rationale

A skilled practitioner would recognize that the source patent's self-emulsifying cannabidiol composition provides a foundational framework that can be readily adapted for specific medical applications by incorporating targeted therapeutic agents or modifying excipient compositions. The PTD's variations represent predictable extensions of the original formulation technology, utilizing standard pharmaceutical engineering techniques to address specific patient populations or treatment scenarios. The core self-emulsification technology remains consistent, with modifications representing routine optimization within the field.

Obvious Combinations & Variations

Source Patent Element
Self-emulsifying cannabidiol composition with surfactants and variable cannabidiol concentrations
PTD Variation
Adding opioid receptor antagonist for addiction treatment
Obviousness Reasoning
Combining therapeutic agents is a standard pharmaceutical design approach, and a PHOSITA would recognize the predictable benefit of enhancing addiction treatment efficacy through targeted receptor interactions
Source Patent Element
Composition with temperature-stable surfactant systems
PTD Variation
Adapting formulation for extreme temperature resistance in chemotherapy patient treatments
Obviousness Reasoning
Modifying pharmaceutical compositions for specific environmental conditions represents a routine engineering optimization within drug delivery technologies
Source Patent Element
Cannabidiol composition with multiple surfactant options
PTD Variation
Incorporating flavoring agents for veterinary applications
Obviousness Reasoning
Adapting pharmaceutical formulations for different species by adding palatability enhancers is a well-established practice in veterinary medicine
Source Patent Element
Self-emulsifying system with variable excipient compositions
PTD Variation
Adding pediatric-friendly excipients for child anxiety treatment
Obviousness Reasoning
Modifying pharmaceutical compositions to improve patient acceptability and compliance is a standard design consideration in pediatric pharmaceutical development
Source Patent Element
Cannabidiol composition with multiple potential therapeutic applications
PTD Variation
Including sleep-promoting agents for elderly patients
Obviousness Reasoning
Combining complementary therapeutic agents to address specific patient population needs represents a predictable pharmaceutical engineering approach
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857678, the present publication demonstrates that a person having ordinary skill in the art would find the disclosed cannabidiol formulation variations obvious and predictable extensions of existing self-emulsifying drug delivery technologies. The modifications represent routine pharmaceutical engineering practices that would be apparent to a skilled practitioner without requiring inventive insight beyond the scope of ordinary professional capabilities.

Original Patent Information

Patent NumberUS 11,857,678
TitleSelf-emulsifying cannabidiol formulations
Assignee(s)Benuvia Operations, LLC